3,6-Dichloropyrazine-2-Carbonitrile CAS 356783-16-9 Purity ≥99.0% (HPLC) Favipiravir Intermediate COVID-19

Short Description:

Chemical Name: 3,6-Dichloropyrazine-2-Carbonitrile

CAS: 356783-16-9

Appearance: Pale Yellow to Off-White Powder

Purity: ≥99.0% (HPLC) 

Intermediate of Favipiravir (CAS: 259793-96-9) in the treatment of patients with COVID-19 recommended by WHO

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Product Detail

Related Products

Product Tags


Chemical Properties:

Chemical Name 3,6-Dichloropyrazine-2-Carbonitrile
Synonyms 3,6-Dichloro-2-Pyrazinecarbonitrile; Favipiravir Impurity 18
CAS Number 356783-16-9
CAT Number RF-PI226
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C5HCl2N3
Molecular Weight 173.99
Brand Ruifu Chemical


Item Specifications
Appearance Pale Yellow to Off-White Powder
Identification HPLC The retention time of the major peak according with reference standard
Moisture (K.F) ≤1.0%
Residue on Ignition ≤0.30%
Single Impurity ≤0.5%
Total Impurities ≤1.0%
Heavy Metals  ≤20ppm
Purity ≥99.0%
Test Standard Enterprise Standard
Usage Intermediate of Favipiravir (CAS: 259793-96-9)

Package & Storage:

Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.





Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 3,6-Dichloropyrazine-2-Carbonitrile (CAS: 356783-16-9) with high quality. It is an intermediate typically in the synthesis of 6-Fluoro-3-Hydroxypyrazine-2-Carboxamide commercially named Favipiravir (CAS: 259793-96-9).
Favipiravir (CAS: 259793-96-9) in the treatment of Influenza virus infections. Favipiravir is a broad-spectrum antiviral drug that was cleared by the Drugs Controller General of India (DCGI) last week for “emergency restricted” use among Covid-19 patients. Glenmark will sell the generic favipiravir under the brand name FabiFlu. Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza.

  • Write your message here and send it to us